<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863576</url>
  </required_header>
  <id_info>
    <org_study_id>0037.0.009.000-10</org_study_id>
    <nct_id>NCT01863576</nct_id>
  </id_info>
  <brief_title>Effects of Omega-3 Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy</brief_title>
  <official_title>Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy: a Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evandro Chagas Institute of Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Andrea Silvestre de Sousa, MD PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alejandro Marcel Hasslocher, MD MSc PhD student</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Andrea Pereira de Souza, PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Claudia Santos de Aguiar Cardoso, MSc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Patricia Dias de Brito, PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pedro Emmanuel Alvarenga Americano do Brasil, MD PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roberta Olmo Pinheiro, PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roberto Magalhães Saraiva, MD PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sergio Salles Xavier, MD PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paula Simplicio da Silva, MSc PhD student</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Evandro Chagas Institute of Clinical Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to study the effects of omega-3 PUFA supplementation on the
      inflammatory response and lipid profile in patients with chronic Chagas cardiomyopathy.

      Study Type: Interventional

      Study Design: A total 40 patients will be randomly assigned into two parallel groups. The
      intervention will be treatment with omega-3 PUFAs at a dose of 3 g/day for 8 weeks, compared
      to placebo (corn oil). The primary endpoints will be the concentrations of inflammatory
      markers (IL-1, IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-γ, and TGF-β). Secondary endpoints
      will be the fasting glucose, lipid, and anthropometric profiles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies have shown the beneficial effects of polyunsaturated fatty acids on
      inflammatory processes, dyslipidemia, and cardiovascular diseases, there are no reports about
      food intake and PUFA supplementation in chronic Chagas cardiomyopathy patients. Thus, the
      objective of this study is to assess the effects of omega-3 PUFA supplementation on the lipid
      profile and the pro-inflammatory and anti-inflammatory cytokine profiles in chronic Chagas
      cardiomyopathy patients.

      After patients are selected by cardiologists, they will be seen by study nutritionists, who
      will explain the study procedures to the patients and administer the free and informed
      consent form. The patients who agree to participate in the study will sign the consent form
      and undergo the initial assessment.

      The following data will be collected and evaluated in the study: sociodemographic data (age,
      sex, ethnicity/race, education, and domicile), clinical data (functional class and vital
      signs), alcoholism, smoking, prescription drugs, 3-day food record, 24-hour recall,
      anthropometric assessment (height, weight, BMI, waist circumference, tricipital skinfold
      thickness, and arm circumference), lipid profile (total cholesterol, triglycerides, HDL-c,
      LDL-c, and VLDL-c), and cytokines (IL-1, IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-γ, and
      TGF-β). Clinical, nutritional, and anthropometric assessments will take place immediately
      before starting the intervention and after 4 and 8 weeks during the study; lipid profile and
      cytokines will be evaluated before the intervention and at the end of 8 weeks. Each patient
      will be followed for 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine profile</measure>
    <time_frame>8 weeks</time_frame>
    <description>The primary endpoint of this study will be the cytokine profile. IL-1, IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-γ, and TGF-β will be measured in the serum of patients using specific sandwich enzyme-linked immunosorbent assays. Capture and detection antibodies will be obtained from eBioscience (San Diego, CA, USA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>8 weeks</time_frame>
    <description>Total cholesterol, triglycerides, and high-density lipoprotein cholesterol (HDL-c) will be measured with enzymatic-colorimetric assays using Siemens reagents on a Siemens Dimension RXL chemistry analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY, USA). Low-density lipoprotein cholesterol (LDL-c) and VLDL-c will be calculated according to the Friedewald equation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anthropometric measures</measure>
    <time_frame>8 weeks</time_frame>
    <description>The anthropometric assessment will consist of body mass index (BMI), waist circumference, tricipital skinfold thickness, and arm circumference.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Chagas Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group is receiving omega-3 supplement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oil Corn</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group is receiving the placebo comparator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3</intervention_name>
    <description>The group omega-3 receives 5 capsules / day, each capsule containing 1100mg of lipids, and 600 mg of omega-3, 3g of omega-3 per day (1.8 g EPA and 1.2 g DHA) for a period of 8 weeks.</description>
    <arm_group_label>Omega-3</arm_group_label>
    <other_name>Oil fish</other_name>
    <other_name>omega 3 fatty acids</other_name>
    <other_name>polyunsaturated fatty acids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>The group placebo receives 5 capsules / day of corn oil containing 1100mg each, for a period of 8 weeks.</description>
    <arm_group_label>Oil Corn</arm_group_label>
    <other_name>Oil Corn</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Volunteers with Chagas Cardiomyopathy at stage B (no heart failure symptoms but with
             segmental or global left ventricular systolic dysfunction), stage C (symptomatic heart
             failure), or stage D (end-stage heart failure)), according to the current Brazilian
             Chagas' Disease Consensus;

          -  Subjects will include adults, men and women.

        Exclusion Criteria:

          -  diarrheal disease;

          -  inflammatory bowel syndrome;

          -  diagnosis of diabetes or other endocrine pathologies;

          -  use of fibrates, niacin, or statins;

          -  use of anti-inflammatory drugs;

          -  pregnant and lactating women;

          -  vitamin mineral or omega-3 supplementation during the previous 30 days;

          -  hospital admission during the study;

          -  presence of cardiomyopathies other than Chagas Cardiomyopathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea S Sousa, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Evandro Chagas Institute of Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evandro Chagas Institute of Clinical Research</name>
      <address>
        <city>RJ</city>
        <state>Br</state>
        <zip>21040-360</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>May 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>September 8, 2016</last_update_submitted>
  <last_update_submitted_qc>September 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Evandro Chagas Institute of Clinical Research</investigator_affiliation>
    <investigator_full_name>Gilberto Marcelo Sperandio da Silva</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Chagas disease</keyword>
  <keyword>Chagas Cardiomyopathy</keyword>
  <keyword>Trypanosoma cruzi</keyword>
  <keyword>Omega-3</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Lipid profile</keyword>
  <keyword>Nutritional assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Chagas Cardiomyopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

